Company Profile
Insmed Stock Price, News & Analysis
- Ticker:
- INSM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
132.55 USD (+33.86%)
Close
Last updated: August 6, 2026
22.5B USD
Market cap
Why the stock is moving
Following the latest company update, “Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update”, INSM closed up 33.9% at $132.55 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Serious and Rare Diseases
Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs.
Commercial Respiratory Portfolio
BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis bronchiectasis. ARIKAYCE is an inhaled liposomal amikacin therapy for *Mycobacterium avium* complex lung disease.
TPIP
Treprostinil palmitil inhalation powder is a long-acting inhaled prostanoid in Phase 3 development for pulmonary arterial hypertension, with additional programs planned in progressive and idiopathic pulmonary fibrosis.
Earlier Pipeline
INS1033 is a second DPP1 inhibitor approaching the clinic, while INS1203 is a gene-therapy candidate for Stargardt disease.
Future catalysts
Japanese regulatory decision for brensocatib during 2026.
TPIP Phase 2b open-label-extension data in the third quarter of 2026.
Supplemental NDA submission for ARIKAYCE in the second half of 2026.
IND filings for INS1033 and INS1203 during 2026.
Initiation of a Phase 3 TPIP study in progressive pulmonary fibrosis by year-end 2026 and in idiopathic pulmonary fibrosis in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Insmed (INSM)?
Insmed (INSM) most recently closed at 132.55 USD, a +33.86% move versus the previous session.
What is the market cap of Insmed (INSM)?
Insmed currently has a market capitalization of 22.5B USD on BioPharmSignal.
What does Insmed do?
Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs. Commercial Respiratory Portfolio BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis bronchiectasis....
On which exchange is INSM stock listed?
Insmed (INSM) is associated with NASDAQ, United States, Biopharma.
What is Serious?
Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases.
Which conditions is Insmed targeting with Serious?
Insmed is associated with rare disease, respiratory disease based on its company overview and current catalyst commentary.
How does Insmed describe recent progress with Serious?
Japanese regulatory decision for brensocatib during 2026. TPIP Phase 2b open-label-extension data in the third quarter of 2026. Supplemental NDA submission for ARIKAYCE in the second half of 2026. IND filings for INS1033 and INS1203 during 2026. Initiation of a Phase 3 TPIP study in progressive pulmonary fibrosis by year-end 2026 and in idiopathic pulmonary...
What is Rare?
Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases.